{"id":1478,"date":"2021-07-28T10:14:56","date_gmt":"2021-07-28T07:14:56","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=1478"},"modified":"2021-07-28T11:00:59","modified_gmt":"2021-07-28T08:00:59","slug":"hpv","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=1478","title":{"rendered":"D\u00fcnyada 292 Milyon, T\u00fcrkiye\u2019de ise Yakla\u015f\u0131k  2 Milyon Ki\u015fi HBV ile Enfekte"},"content":{"rendered":"<p><strong>Alan\u0131nda \u0130lk Olan \u2018Kronik Hepatit B Hasta Kay\u0131t \u00c7al\u0131\u015fmas\u0131\u2019 ile <\/strong><strong>kronik hepatit B tan\u0131 ve tedavisinde kullanmak \u00fczere \u00f6nemli istatistiksel veriler elde edilecek.<\/strong><\/p>\n<p>28 Temmuz D\u00fcnya Hepatit Fark\u0131ndal\u0131k G\u00fcn\u00fc dolay\u0131s\u0131 ile Viral Hepatitle Sava\u015f\u0131m Derne\u011fi ev sahipli\u011finde d\u00fczenlenen bas\u0131n toplant\u0131s\u0131nda halk sa\u011fl\u0131\u011f\u0131n\u0131 \u00f6nemli derecede tehdit eden bu hastal\u0131ktan korunma yollar\u0131 ve tedavisindeki yakla\u015f\u0131mlar ve alan\u0131nda ilk olan \u2018Kronik Hepatit B Hasta Kay\u0131t \u00c7al\u0131\u015fmas\u0131\u2019 n\u0131n detaylar\u0131 payla\u015f\u0131ld\u0131.<\/p>\n<p>Bas\u0131n toplant\u0131s\u0131na,\u00a0 Viral Hepatitle Sava\u015f\u0131m Derne\u011fi Y\u00f6netim Kurulu Ba\u015fkan\u0131 ve \u0130stanbul \u00dcniversitesi Cerrahpa\u015fa T\u0131p Fak\u00fcltesi \u00a0Enfeksiyon Hastal\u0131klar\u0131 ve Klinik Mikrobiyoloji Anabilim Dal\u0131 Ba\u015fkan\u0131 <strong>Prof. Dr. Fehmi Tabak, <\/strong>Ankara Y\u0131ld\u0131r\u0131m Beyaz\u0131t \u00dcniversitesi Ankara \u015eehir Hastanesi\u00a0 Enfeksiyon Hastal\u0131klar\u0131 Klini\u011fi \u0130dari ve E\u011fitim Sorumlusu <strong>Prof. Dr. Hatice Rahmet G\u00fcner <\/strong>ile \u0130stanbul \u00dcniversitesi \u0130stanbul T\u0131p Fak\u00fcltesi \u0130\u00e7 Hastal\u0131klar\u0131 Anabilim Dal\u0131 Gastroenterohepatoloji Bilim Dal\u0131 Ba\u015fkan\u0131 <strong>Prof. Dr. Sabahattin Kaymako\u011flu <\/strong>konu\u015fmac\u0131 olarak kat\u0131ld\u0131.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-1495 size-thumbnail\" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2021\/07\/IMG_7048-1-150x150.jpg\" alt=\"\" width=\"150\" height=\"150\" \/><\/p>\n<p><strong>Viral Hepatitle Sava\u015f\u0131m Derne\u011fi Y\u00f6netim Kurulu Ba\u015fkan\u0131 Prof. Dr. Fehmi Tabak, t\u00fcm d\u00fcnyada yakla\u015f\u0131k 257 milyon hepatit B, 71 milyon da hepatit C ta\u015f\u0131y\u0131c\u0131s\u0131 veya hastas\u0131 bulundu\u011funu belirterek \u015fu bilgileri payla\u015ft\u0131: <\/strong>\u201cHepatit B ve hepatit C vir\u00fcsleri t\u00fcm d\u00fcnyada oldu\u011fu gibi \u00fclkemizde de \u00f6nemli bir sa\u011fl\u0131k sorunudur. \u00dclkemizde HBV s\u0131kl\u0131\u011f\u0131\u00a0 y\u00fczde 4, HCV s\u0131kl\u0131\u011f\u0131 ise y\u00fczde 1 olup, yakla\u015f\u0131k 2 milyon hepatit B ve 300 -400 bin hepatit C hastam\u0131z oldu\u011fu tahmin edilmektedir. Hepatit C hastalar\u0131m\u0131z\u0131n tan\u0131 koyuldu\u011funda y\u00fczde 20\u2019sinin ileri evrede yani sirotik olmas\u0131 \u00e7ok ac\u0131 bir ger\u00e7ektir. T\u00fcm d\u00fcnyada bir y\u0131lda 1.3 milyona yak\u0131n ki\u015fi hepatit B (HBV) ve hepatit C vir\u00fcs\u00fcn\u00fcn (HCV) yol a\u00e7t\u0131\u011f\u0131 kronik hepatitlere ba\u011fl\u0131 komplikasyon olarak geli\u015fen siroz ve karaci\u011fer kanseri nedeniyle kaybedilmektedir.<\/p>\n<p>Hepatit B ve C vir\u00fcsle enfekte olmu\u015f kan ve kan \u00fcr\u00fcnleriyle, steril olmayan aletlerle yap\u0131lan t\u0131bbi ve cerrahi giri\u015fimlerle, damar i\u00e7i uyu\u015fturucu kullan\u0131m\u0131yla, d\u00f6vme ve piercing uygulamalar\u0131 ile do\u011fum s\u0131ras\u0131nda anneden \u00e7ocu\u011fa ve nadiren de olsa vir\u00fcs\u00fc ta\u015f\u0131yan ki\u015fiyle girilen korunmas\u0131z cinsel ili\u015fkiyle bula\u015fmaktad\u0131r.<\/p>\n<p><strong>Hepatit B ve C\u2019nin tedavisi var m\u0131d\u0131r?<\/strong><\/p>\n<p>Bug\u00fcn kronik hepatit B tedavi ile kontrol alt\u0131na al\u0131nabilir, kronik hepatit C\u2019de tedavi edilebilir bir hastal\u0131k konumuna gelmi\u015ftir. Yakla\u015f\u0131k 5 y\u0131ld\u0131r hepatit C hastalar\u0131m\u0131z\u0131n yeni antiviraller ile tedavisi SGK taraf\u0131ndan kar\u015f\u0131lanmaktad\u0131r. Bu tedavilerin ba\u015far\u0131 oran\u0131 da neredeyse y\u00fczde 100\u2019e yak\u0131nd\u0131r ve hastal\u0131k bir daha tekrarlamamaktad\u0131r.<\/p>\n<p>Hepatit B vir\u00fcs (HBV) enfeksiyonu a\u015f\u0131yla korunulabilir bir hastal\u0131kt\u0131r. Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 1998 y\u0131l\u0131ndan beri hepatit B a\u015f\u0131s\u0131n\u0131 \u00e7ocukluk a\u015f\u0131 program\u0131na alm\u0131\u015f olup, y\u00fczde 90\u2019lar\u0131n \u00fczerinde ba\u015far\u0131 ile bu program\u0131na devam etmektedir. Yakla\u015f\u0131k 30 y\u0131ld\u0131r hepatit B veya hepatit C\u2019ye ba\u011fl\u0131 kronik hepatitler tedavi edilebilmektedir. Kronik hepatit B tedavisinde de\u011fi\u015fik say\u0131da tedavi s\u00f6z konusu olup, hastalar g\u00fcnde 1 tablet ile tedavi edilebilmektedir. 30 y\u0131l \u00f6nce ba\u015flayan hepatit C tedavisinde bug\u00fcn i\u00e7in yeni tedavi y\u00f6ntemleri ile 2-3 ay gibi k\u0131sa s\u00fcrede hastalar\u0131m\u0131z\u0131n nerede ise tamam\u0131 tedavi edilebilmektedir. \u00dclkemizde hepatit B ve C hastalar\u0131, d\u00fcnya standartlar\u0131 \u00f6l\u00e7\u00fcs\u00fcnde tedavi imkan\u0131na kavu\u015fmu\u015flard\u0131r.<\/p>\n<p>Hepatit C ile ili\u015fkili hastal\u0131k y\u00fck\u00fcn\u00fcn \u00f6n\u00fcm\u00fczdeki birka\u00e7 on y\u0131l i\u00e7inde artaca\u011f\u0131 \u00f6ng\u00f6r\u00fclmektedir. Tedavi edilen hastalarda siroz ve kansere ba\u011fl\u0131 \u00f6l\u00fcmleri \u00f6nemli \u00f6l\u00e7\u00fcde azaltmaktad\u0131r. COVID-19 pandemisi yeni tan\u0131 koymada ve tedavide aksakl\u0131klara yol a\u00e7m\u0131\u015ft\u0131r. Tedavinin gecikmesi uzun d\u00f6nemde maliyetleri art\u0131rmaktad\u0131r. Bug\u00fcn i\u00e7in tedavi edilebilen bu hastal\u0131kta fark\u0131ndal\u0131\u011f\u0131 art\u0131rmak \u00e7ok \u00f6nemli bir hale gelmi\u015ftir.\u201d<\/p>\n<p><strong>Kronik hepatit B (KHB) tedavi alan\u0131nda bir ilk: Kronik Hepatit B Hasta Kay\u0131t \u00c7al\u0131\u015fmas\u0131 <\/strong><\/p>\n<p><strong> <img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-1484 size-thumbnail\" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2021\/07\/Rahmet-Guner-150x150.jpeg\" alt=\"\" width=\"150\" height=\"150\" srcset=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2021\/07\/Rahmet-Guner-150x150.jpeg 150w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2021\/07\/Rahmet-Guner-298x300.jpeg 298w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2021\/07\/Rahmet-Guner.jpeg 332w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/strong><\/p>\n<p><strong>Ankara Y\u0131ld\u0131r\u0131m Beyaz\u0131t \u00dcniversitesi Ankara \u015eehir Hastanesi\u00a0 Enfeksiyon Hastal\u0131klar\u0131 Klini\u011fi \u0130dari ve E\u011fitim Sorumlusu Prof. Dr. Hatice Rahmet G\u00fcner, kronik hepatit B (KHB) tedavi alan\u0131nda bir ilk olan \u2018Kronik Hepatit B Hasta Kay\u0131t \u00c7al\u0131\u015fmas\u0131\u2019n\u0131n detaylar\u0131n\u0131 payla\u015ft\u0131. G\u00fcner, <\/strong>\u201cT\u00fcrkiye\u2019de KHB tedavi alan\u0131nda ilk olacak olan hasta kay\u0131t \u00e7al\u0131\u015fmas\u0131, \u00fclkemizde kronik hepatit B hasta yolculu\u011funu ortaya koymak, ulusal bir veri taban\u0131 eksikli\u011fini tamamlamak, karar vericilere kaynak sa\u011flamak a\u00e7\u0131s\u0131ndan olduk\u00e7a b\u00fcy\u00fck \u00f6nem ta\u015f\u0131maktad\u0131r. Retrospektif yani geriye d\u00f6n\u00fck \u00e7al\u0131\u015fmalar; epidemiyolojik s\u00fcrveyans, hastal\u0131\u011f\u0131n de\u011ferlendirilmesi ve tedavinin sa\u011fkal\u0131m ve hastal\u0131\u011f\u0131n ilerlemesi \u00fczerindeki etkisi \u00fczerinde \u00f6nemli bir katk\u0131 sa\u011flamaktad\u0131r.<\/p>\n<p>Hastane kay\u0131tlar\u0131ndan elde edilen verilerle birincil ama\u00e7 kronik hepatit B hastal\u0131\u011f\u0131nda tedavi etkilili\u011finin de\u011ferlendirilmesidir. \u00c7al\u0131\u015fma sayesinde \u00fclkemiz KHB tan\u0131 ve tedavisinde \u00f6nemli istatiksel veriler elde edilecektir. Geriye d\u00f6n\u00fck bilgilerin topland\u0131\u011f\u0131 bu \u00e7al\u0131\u015fmaya 2010 ve 2020 y\u0131llar\u0131 aras\u0131nda kronik hepatit B tan\u0131s\u0131 alm\u0131\u015f ve t\u0131bbi kay\u0131tlarla belgelenmi\u015f t\u00fcm hastalar dahil edilecektir. T\u00fcrkiye\u2019de 17 enfeksiyon merkezinden 5 bin hastan\u0131n kay\u0131t alt\u0131na al\u0131nmas\u0131 planlanmaktad\u0131r. Hastane kay\u0131tlar\u0131ndan elde edilen veriler elektronik olgu rapor formu ile toplanacakt\u0131r. Geriye d\u00f6n\u00fck hasta kay\u0131t verilerinin tamamlanmas\u0131n\u0131n ard\u0131ndan, \u00e7al\u0131\u015fman\u0131n ileriye d\u00f6n\u00fck de devam\u0131 planlanmaktad\u0131r. Bu sayede artan merkez ve hasta say\u0131lar\u0131 ile beraber ulusal KHB hasta kay\u0131t sistemi olu\u015fturulmu\u015f olacak. Bu veriler de bir\u00e7ok kongre ve dernekler arac\u0131l\u0131\u011f\u0131 ile hekimlerimiz ile bulu\u015facak ve karar vericilere \u00f6nemli bir kaynak olacakt\u0131r. B\u00fcy\u00fck bir heyecanla ba\u015flad\u0131\u011f\u0131m\u0131z bu kay\u0131t \u00e7al\u0131\u015fmas\u0131n\u0131n uzun y\u0131llar biz ve bizden sonraki nesiller taraf\u0131ndan da devam ettirilmesini; \u00fclkemize, hastalar\u0131m\u0131za ve hekimlerimize yard\u0131mc\u0131 olmas\u0131n\u0131 dileriz\u201d dedi.<\/p>\n<p><strong>\u00a0<\/strong><strong><em>DS\u00d6, halk sa\u011fl\u0131\u011f\u0131 tehdidi olan viral hepatiti 2030 y\u0131l\u0131na kadar ortadan kald\u0131rmak i\u00e7in t\u00fcm \u00fclkeleri birlikte \u00e7al\u0131\u015fmaya \u00e7a\u011f\u0131r\u0131yor! <\/em><\/strong><\/p>\n<p><strong><em> <img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-1485 size-thumbnail\" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2021\/07\/Sabahattin-Kaymakoglu-150x150.jpg\" alt=\"\" width=\"150\" height=\"150\" \/><\/em><\/strong><\/p>\n<p><strong>\u0130stanbul <\/strong><strong>\u00dcniversitesi \u0130stanbul T\u0131p Fak\u00fcltesi <\/strong><strong>\u0130\u00e7 Hastal\u0131klar\u0131 Anabilim Dal\u0131 Gastroenterohepatoloji Bilim Dal\u0131 Ba\u015fkan\u0131 Prof. Dr. Sabahattin Kaymako\u011flu da DS\u00d6\u2019n\u00fcn bu sa\u011fl\u0131k sorunu ile ilgili yapmakta oldu\u011fu \u00e7al\u0131\u015fmalara dikkat \u00e7ekerek \u015f\u00f6yle konu\u015ftu: <\/strong>\u201c\u00d6ncelikli m\u00fcdahale gerektiren \u00f6nemli bir halk sa\u011fl\u0131\u011f\u0131 sorunu olan viral hepatit, COVID-19 salg\u0131n\u0131n\u0131n ortas\u0131nda da binlerce can almaya devam ediyor. DS\u00d6 verilerine g\u00f6re, her 30 saniyede bir ki\u015fi hepatitle ili\u015fkili hastal\u0131ktan ya\u015fam\u0131n\u0131 kaybediyor. Karaci\u011fer kanseri de dahil olmak \u00fczere bir dizi sa\u011fl\u0131k sorununa neden olan viral hepatite kar\u015f\u0131 fark\u0131ndal\u0131\u011f\u0131 art\u0131rmak i\u00e7in 28 Temmuz, D\u00fcnya Hepatit G\u00fcn\u00fc olarak de\u011ferlendiriliyor.\u00a0 Her y\u0131l farkl\u0131 temalarla \u00e7e\u015fitli fark\u0131ndal\u0131k \u00e7al\u0131\u015fmalar\u0131 y\u00fcr\u00fct\u00fcl\u00fcyor.\u00a0 D\u00fcnya Hepatit G\u00fcn\u00fc 2021 y\u0131l\u0131 temas\u0131; <strong>\u2018<\/strong><strong>Hepatit bekleyemez\u2019<\/strong> slogan\u0131 ile hepatitin bir halk sa\u011fl\u0131\u011f\u0131 tehdidi olarak 2030 y\u0131l\u0131na kadar ortadan kald\u0131r\u0131lmas\u0131 i\u00e7in gereken \u00e7abalar\u0131n aciliyetini aktarmak hedefleniyor.<\/p>\n<p>DS\u00d6&#8217;n\u00fcn 194 \u00fcye devleti, viral hepatitleri 2030 y\u0131l\u0131na kadar bir halk sa\u011fl\u0131\u011f\u0131 tehdidi olarak ortadan kald\u0131rmay\u0131 taahh\u00fct etti. Tan\u0131 oranlar\u0131nda y\u00fczde 90\u2019a tedavi oranlar\u0131nda y\u00fczde 80\u2019e ula\u015farak \u00f6l\u00fcm oranlar\u0131nda y\u00fczde 65 azalma sa\u011flanmas\u0131 k\u00fcresel hedefler aras\u0131nda yer al\u0131yor.<\/p>\n<p>Bu \u00f6nemli halk sa\u011fl\u0131\u011f\u0131 sorununun ortadan kald\u0131r\u0131lmas\u0131 be\u015f sinerjik \u00f6nleme ve tedavi m\u00fcdahalesi ile sa\u011flanabilir:<\/p>\n<ul>\n<li>G\u00f6zetim ve program verilerine dayal\u0131 stratejik bir bilgi sisteminin geli\u015ftirilmesi<\/li>\n<li>Test ve tedaviye y\u00f6nelik hizmet kapsam\u0131n\u0131n h\u0131zla b\u00fcy\u00fct\u00fclmesi<\/li>\n<li>Viral hepatitlere y\u00f6nelik hizmetlerin herkese fayda sa\u011flamak i\u00e7in bir halk sa\u011fl\u0131\u011f\u0131 yakla\u015f\u0131m\u0131yla sunulmas\u0131<\/li>\n<li>2030 S\u00fcrd\u00fcr\u00fclebilir Kalk\u0131nma G\u00fcndemi\u2019nde sa\u011fl\u0131k i\u00e7in iyi bir \u00e7er\u00e7eve olan evrensel sa\u011fl\u0131k kapsam\u0131n\u0131 m\u00fcmk\u00fcn k\u0131lmak i\u00e7in s\u00fcrd\u00fcr\u00fclebilir finansman temini<\/li>\n<li>Eliminasyon hedeflerine ula\u015fmak i\u00e7in yeni te\u015fhis ve a\u015f\u0131lama y\u00f6ntemlerinin acilen geli\u015ftirilmesi, test edilmesi ve sunulmas\u0131.<\/li>\n<\/ul>\n<p>Viral hepatite k\u00fcresel yan\u0131tta erken bir kazan\u00e7, hepatit B a\u015f\u0131s\u0131n\u0131n etkili bir \u015fekilde \u00f6l\u00e7eklendirilmesiyle elde edildi. 2015 y\u0131l\u0131nda, bebeklik d\u00f6neminde \u00fc\u00e7 doz hepatit B a\u015f\u0131s\u0131 ile k\u00fcresel kapsam y\u00fczde 84&#8217;e ula\u015ft\u0131. Bununla birlikte, ilk do\u011fum dozu a\u015f\u0131lamas\u0131n\u0131n kapsam\u0131 h\u00e2l\u00e2 y\u00fczde 39 oran\u0131ndad\u0131r.<\/p>\n<p><strong>T\u00fcrkiye\u2019de yakla\u015f\u0131k 950 bin karaci\u011fer sirozlu ve 75 bin karaci\u011fer kanserli hasta var. \u00dclkemizdeki karaci\u011fer sirozu ve karaci\u011fer kanserlerinin y\u00fczde 60\u2019\u0131ndan hepatit B, C ve D vir\u00fcsleri sorumludur.\u00a0\u00a0 T\u00fcrkiye\u2019de tan\u0131 konmay\u0131 bekleyen hepatit B ile enfekte 1.5 milyon ve hepatit C ile enfekte 270 bin eri\u015fkin var. Viral hepatitlerle ilgili toplumsal fark\u0131ndal\u0131\u011f\u0131n art\u0131r\u0131lmas\u0131, T\u00fcrkiye Viral Hepatit \u00d6nleme ve Kontrol Program\u0131\u2019ndaki aksiyonlar\u0131n gecikmeksizin devreye sokulmas\u0131 \u00fclkemizdeki viral hepatitlerin eliminasyonu hedeflerine ula\u015f\u0131lmas\u0131ndaki temel ta\u015flar olacakt\u0131r.\u201d<\/strong><\/p>\n<p><strong><em>Hepatitsiz bir gelecek, ortak bir \u00e7aba ile elde edilebilir<\/em><\/strong><\/p>\n<p><strong><em><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-1479 alignleft\" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2021\/07\/1.jpg\" alt=\"\" width=\"57\" height=\"62\" \/>YEN\u0130DO\u011eANLAR ARASINDA ENFEKS\u0130YONU \u00d6NLEY\u0130N<\/em><\/strong><\/p>\n<p>T\u00fcm yenido\u011fanlar do\u011fumda hepatit B&#8217;ye kar\u015f\u0131 a\u015f\u0131lanmal\u0131 ve ard\u0131ndan en az 2 ek doz uygulanmal\u0131d\u0131r.<\/p>\n<p><strong><em>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 ANNEDEN \u00c7OCU\u011eA BULA\u015eI DURDURUN<\/em><\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-1480 \" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2021\/07\/2.jpg\" alt=\"\" width=\"51\" height=\"56\" \/>T\u00fcm hamile kad\u0131nlar rutin olarak hepatit B, C, HIV ve sifiliz i\u00e7in test edilmeli ve gerekirse tedavi g\u00f6rmelidir.<\/p>\n<p>&nbsp;<\/p>\n<p><strong><em>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0ARKADA K\u0130MSEY\u0130 BIRAKMAYIN<\/em><\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-1481 \" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2021\/07\/3.jpg\" alt=\"\" width=\"61\" height=\"61\" \/>Damar i\u00e7i madde kullananlar, mahkumlar, endemik \u00fclke g\u00f6\u00e7menleri, \u00e7ok partnerli seks\u00fcel ili\u015fkiler gibi viral hepatitler i\u00e7in ciddi risk grubunda olan gruplar dahil herkesin hepatit \u00f6nleme, test ve tedavi hizmetlerine kolayca eri\u015fimi sa\u011flanmal\u0131d\u0131r.<\/p>\n<p>&nbsp;<\/p>\n<p><strong><em>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0TEST VE TEDAV\u0130YE ER\u0130\u015e\u0130M\u0130 GEN\u0130\u015eLET\u0130N<\/em><\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-1482\" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2021\/07\/4.jpg\" alt=\"\" width=\"65\" height=\"70\" \/>Viral hepatitin zaman\u0131nda test edilmesi ve tedavisi, karaci\u011fer kanserini ve karaci\u011fer sirozunu \u00f6nleyebilir.<\/p>\n<p>&nbsp;<\/p>\n<p><strong><em>COVID-19<\/em><\/strong><strong><em> SIRASINDA TEMEL HEPAT\u0130T H\u0130ZMETLER\u0130N\u0130 S\u00dcRD\u00dcR\u00dcN<\/em><\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-1483 \" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2021\/07\/5.jpg\" alt=\"\" width=\"67\" height=\"69\" \/>Hepatit \u00f6nleme ve tan\u0131-tedavi hizmetlerinin (bebek a\u015f\u0131s\u0131, hasar azaltma hizmetleri ve kronik hepatit B&#8217;nin s\u00fcrekli tedavisi gibi) pandemi s\u0131ras\u0131nda aksat\u0131lmadan s\u00fcrd\u00fcr\u00fclmesi \u00e7ok \u00f6nemlidir.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alan\u0131nda \u0130lk Olan \u2018Kronik Hepatit B Hasta Kay\u0131t \u00c7al\u0131\u015fmas\u0131\u2019 ile kronik hepatit B tan\u0131 ve tedavisinde kullanmak \u00fczere \u00f6nemli istatistiksel veriler elde edilecek. 28 Temmuz D\u00fcnya Hepatit Fark\u0131ndal\u0131k G\u00fcn\u00fc dolay\u0131s\u0131 ile Viral Hepatitle Sava\u015f\u0131m Derne\u011fi ev sahipli\u011finde d\u00fczenlenen bas\u0131n toplant\u0131s\u0131nda halk sa\u011fl\u0131\u011f\u0131n\u0131 \u00f6nemli derecede tehdit eden bu hastal\u0131ktan korunma yollar\u0131 ve tedavisindeki yakla\u015f\u0131mlar ve alan\u0131nda &hellip;<\/p>\n","protected":false},"author":1,"featured_media":1491,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,3],"tags":[69],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/1478"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1478"}],"version-history":[{"count":5,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/1478\/revisions"}],"predecessor-version":[{"id":1496,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/1478\/revisions\/1496"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/1491"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}